• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Breast Cancer Drug Pipeline Update 2015

  • ID: 1197076
  • June 2015
  • Region: Global
  • Bioseeker

Breast cancer is the leading cause of cancer-related mortality among women worldwide. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic setting, the overall survival remains below five years.
There are today 573 companies plus partners developing 699 drugs targeting breast cancer in development. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 235 drugs. Breast Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 430 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 404 out of the 407 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 74 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.


Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

C.R. Bard, Inc. GlaxoSmithKline PLC Hologic Corporation Provista Diagnostics, Inc. Roche Diagnostics Ltd. Genomic Health Inc.